Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure

August 10, 2006 updated by: Abbott

A Phase 2 Study Evaluating the Safety and Efficacy of Atrasentan (ABT-627) in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure

The purpose of this phase II, randomized, double-blind placebo controlled, multi-center study is to evaluate the safety and efficacy of 10 mg atrasentan in hormone naive subjects as measured by rate of rise in the PSA (primary objective).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment

200

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Quebec, Canada, G1R 2J6
        • Chuq Pavillon Hotel-Dieu
    • Alberta
      • Calgary,, Alberta, Canada, T2N 4N2
        • Tom Baker Cancer Center
      • Edmonton, Alberta, Canada, T6G1Z2
        • Cross Cancer Institute
    • British Columbia
      • Surrey, British Columbia, Canada, V3V 1N1
        • Cal Andreou, MD
      • Victoria, British Columbia, Canada
        • Can-Med Medical Research Inc
    • Nova Scotia
      • Kentville, Nova Scotia, Canada, B4N4K9
        • Bruce W. Palmer Urology Inc.
    • Ontario
      • Barrie, Ontario, Canada, L4M 4S5
        • The Male Health Centres
      • Burlington, Ontario, Canada, L7N 3V2
        • Burlington Professional Centre
      • Hamilton,, Ontario, Canada, L8N 1T8
        • Hamilton & District Urology Association
      • London, Ontario, Canada, N6A 4G5
        • London Health Sciences Centre
      • Markham, Ontario, Canada, L6B1A1
        • Quest Clinical Trials
      • North Bay, Ontario, Canada, P1B4Z2
        • Guardian Medical Arts Bldg.
      • North York, Ontario, Canada, M6A 3B5
        • Jack Barkin, MD
      • Oakville, Ontario, Canada, L6H 3P1
        • The Male Health Centres
      • Toronto, Ontario, Canada, M4N 3M5
        • Sunnybrook &Women's College Health Sciens Center
    • Quebec
      • Montreal, Quebec, Canada, H2L 4M1
        • Hôpital Notre-Dame
    • Alabama
      • Homewood,, Alabama, United States, 35205
        • Urology Centers of Alabama
    • Alaska
      • Anchorage, Alaska, United States, 99508
        • Alaska Clinical Research Center, LLC
    • Arkansas
      • Little Rock, Arkansas, United States, 72205
        • Arkansas Urologial Associates, PA
    • California
      • La Mesa, California, United States, 91942
        • San Diego Urology Center
      • Torrance, California, United States, 90505
        • Western Clinical Research Inc
    • District of Columbia
      • Washington, District of Columbia, United States, 20007
        • Georgetown University Medical Center
    • Florida
      • Fort Myers, Florida, United States, 33916
        • Clinical Physiology Associates
      • Tallahassee, Florida, United States, 32308
        • Southeastern Urological Center, PA
    • Illinois
      • Chicago, Illinois, United States, 60611
        • Northwestern University
    • Maryland
      • Baltimore, Maryland, United States, 21231-1000
        • Johns Hopkins Oncology Center
    • Nevada
      • Las Vegas, Nevada, United States, 89109
        • Sheldon Freedman MD
      • Reno, Nevada, United States, 89511
        • Nevada Urology Associates
      • Reno, Nevada, United States, 89502
        • VA Medical Center(111)
    • North Carolina
      • Charlotte,, North Carolina, United States, 28204
        • Carolinas Medical Centre
    • Ohio
      • Cleveland, Ohio, United States, 44195
        • Cleveland Clinic Foundation
    • Oklahoma
      • Tulsa,, Oklahoma, United States, 74104-5433
        • Urologic Specialists of Oklahoma, Inc.
    • Oregon
      • Eugene, Oregon, United States, 97401
        • Oregon Urology Specialists
    • Pennsylvania
      • Lancaster, Pennsylvania, United States, 17604-3200
        • Urological Assoc. of Lancaster
      • Pittsburgh, Pennsylvania, United States, 15232
        • University of Pittsburgh
      • West Reading, Pennsylvania, United States, 19611
        • Center for Urologic Care
      • West Reading,, Pennsylvania, United States, 19611
        • Center for Urologic Care
    • Texas
      • Dallas, Texas, United States, 75230
        • nTouch Research Corporation
    • Utah
      • Salt Lake City, Utah, United States, 84124
        • Salt Lake Research
    • Washington
      • Seattle, Washington, United States, 98195
        • University of Washington Medical Center
      • Seattle,, Washington, United States, 98166-3059
        • Jeffrey Frankel, M.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • prostate adenocarcinoma,
  • radical prostatectomy,
  • PSA between 0.4 and 5 ng/mL,
  • PSADT < 1 year

Exclusion Criteria:

  • previous hormonal therapy,
  • salvage therapy to the pelvis within 3 months prior to randomization

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Evaluate the safety and efficacy of 10mg atrasentan in hormone naive subjects, as measured by the rate of rise in PSA.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Darryl Sleep, M.D., Abbott

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2002

Study Registration Dates

First Submitted

June 3, 2002

First Submitted That Met QC Criteria

June 3, 2002

First Posted (Estimate)

June 4, 2002

Study Record Updates

Last Update Posted (Estimate)

August 15, 2006

Last Update Submitted That Met QC Criteria

August 10, 2006

Last Verified

August 1, 2006

More Information

Terms related to this study

Other Study ID Numbers

  • M01-366

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.